Proteomics

Proteomics                                                    INDI DX ™

Proteins unique to one organ – or one condition – are sentinels of health and disease. Indi is developing diagnostics capable of measuring hundreds of these biomarkers simultaneously to provide the best clinical relevancy. This work is based on the groundbreaking research of Indi co-founder, Dr. Lee Hood, investigating protein blood markers that can report on the physiological state of the body’s 50 major organs. By monitoring concentrations of select proteins in the blood, disruptions in healthy function can be detected and traced back to the diseased organ.

Advanced Technology

Simultaneously measures multiple proteins associated with lung cancer

Xpresys Lung utilizes powerful technology to simultaneously measure multiple circulating proteins associated with lung cancer. Patient blood is analyzed by cutting edge mass spectrometry that provides highly sensitive and specific detection of target proteins. The mass spectrometer can reliably detect circulating proteins at concentrations in the low nanogram per milliliter range.

Relative changes in the circulating levels of the proteins detected by Xpresys Lung are associated with the presence or absence of lung cancer. This enables Xpresys Lung to provide objective molecular insight into the status of a lung nodule in addition to, but independent of other clinical factors such as age, smoking history, nodule size, and COPD diagnosis.

The increase in the relative abundance of the protein is associated with malignant (red) process⁽¹⁾.

Xpresys Lung measures 11 proteins in total. Five diagnostic and six normalization proteins, which are listed below.

<sup>References:
1. Vachani, Anil, MD. "Validation of a Multi-Protein Plasma Classifier to Identify Benign Lung Nodules: Journal of Thoracic Oncology." LWW. Journal of Thoracic Oncology, 14 Jan. 2015. Web. 26 Jan. 2015.</sup>